Non-small cell lung cancer (NSCLC), Small cell lung carcinoma
Other clinical trials
The National Network Genomic Medicine Lung Cancer (nNGM) centralizes molecular diagnostics for non-small cell lung cancer (NSCLC) throughout Germany for the first time. In this way, a comprehensive genetic analysis of the tumor can be made available to all treatment providers during initial therapy planning. For this purpose, comprehensive molecular diagnostics will be offered in specialized nNGM network centers - subsequent treatment can then take place close to home in an oncology practice or in the local hospital.
The National Network Genomic Medicine Lung Cancer (nNGM) centralizes molecular diagnostics for non-small cell lung cancer (NSCLC) throughout Germany for the first time. In this way, a comprehensive genetic analysis of the tumor can be made available to all treatment providers during initial therapy planning. For this purpose, comprehensive molecular diagnostics will be offered in specialized nNGM network centers - subsequent treatment can then take place close to home in an oncology practice or in the local hospital.
